NeuroSense Therapeutics annual free cash flow
2019
2020
2021
2022
2023
2024
2025
NeuroSense Therapeutics Free Cash Flow (FCF) History (NRSN)
NeuroSense Therapeutics reported −$7.7M in free cash flow for fiscal 2025, an increase of $2.5M from the previous fiscal year.
View full NeuroSense Therapeutics company overviewNeuroSense Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$7.7M | $2.5M | — | — |
| 2024 | 2024-12-31 | −$10.1M | −$1.7M | — | — |
| 2023 | 2023-12-31 | −$8.5M | −$825,000 | — | — |
| 2022 | 2022-12-31 | −$7.7M | −$6.1M | — | — |
| 2021 | 2021-12-31 | −$1.6M | −$852,000 | — | — |
| 2020 | 2020-12-31 | −$704,000 | −$115,000 | — | — |
| 2019 | 2019-12-31 | −$589,000 | — | — | — |
NeuroSense Therapeutics quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
NeuroSense Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$704,000 to −$7.7M, a net decrease of $7.0M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review NeuroSense Therapeutics filings at SEC.gov ↗